A Phase 3, Multicentre, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB001078C) Plus Best Supportive Care vs Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy

NMA Reference Number: HREC/16/MonH/124
Monash Health HREC Ref: 16212A